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EPLY
am grateful to Dr.Wharton for his interest in the editorial (1) about
he declining need for emergency bypass surgery for failed percuta-
eous coronary interventions (PCIs) at the Mayo Clinic (2).
The Mayo report (2) and the current PCI guidelines raise the
ssue of what constitutes adequate evidence to perform elective
CIs in community hospitals without on-site bypass surgery.
lthough Wharton et al. (3) showed that direct PCI is superior to
brinolytic therapy for ST-segment elevation myocardial infarc-
ion in a broad range of hospital settings, this level of evidence is
urrently lacking for elective PCIs without on-site bypass surgery
n the U.S. The Mayo report (2) does not prove that it is safe to
erform elective PCIs without on-site surgery in Exeter, New
ampshire, or anywhere else.
The assessment of elective PCIs without on-site bypass surgery
nderway in some states (4) is a step in the right direction.
owever, choosing the right metrics is challenging. An observa-
ional matched cohort analysis constitutes a good start, but results
rom a single pair of closely linked hospitals within one health care
elivery system are not broadly generalizable (5), and statistical
ests for non-inferiority require larger comparison groups.
The motivation to perform an elective PCI without on-site
ypass surgery needs clarification. “During its 28-year-history,
lective PCI has never been shown to extend life or prevent death”
4). The recent proliferation of cardiac procedures in North
merica has not been explained by an increased prevalence of
isease but has generated serious questions about the value to
ndividual patients and society (6). Costs will increase further in
he absence of safeguards to limit the inevitable expansion in the
umber of hospitals performing PCIs.
Finally, the term “hubris” in the editorial (1) has rankled some
eaders. The medical meaning, based on the classical character flaw
f arrogantly flaunting natural law and suffering tragic conse-
uences, connotes more than the dictionary definition. Even the
ost gifted physicians can be humbled by unforeseeable twists and
urns in the response to treatment. But I digress.
John A. Bittl, MD
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r. Wharton’s letter resonates with our practice at two regional
ites with no on-site surgery (1). None of us is immune from
ubris, but by the same token, none of us is either above or below
t (as the case may be), selecting only specific data points on a curve
hat agree with what we hold to be the “truth.” A single publication
r a trial rarely reveals the entire truth, and more data are needed
o discover concordance in the findings. When the results of
ultiple datasets are similar in directionality, degree, and extent,
e can be increasingly confident that we know the answer to the
pecific question posed. We need to remember that the questions
volve as do the answers.
Thus, we agree wholeheartedly with Dr. Wharton about “grow-
ng evidence supporting the current safety of percutaneous coro-
ary intervention [PCI] . . . with off-site surgical backup.” The
hallenge is to increase safe access to this important part of our
herapeutic armamentarium. Programs that have been performing
ff-site PCIs have found that success depends on: 1) careful patient
nd lesion selection; 2) a protocol to rapidly transport patients with
CI complications to centers with on-site surgery; 3) skilled
perators and catheterization laboratory staff who are able to
erform these procedures with a high success rate; and 4) processes
f the patient’s care that will improve the outcomes following PCI.
t will be prudent to establish guidelines for elective PCIs similar
o those proposed by Dr. Wharton for the conduct of primary
CIs (2).
Until further studies evaluating the safety of off-site PCI can be
erformed, we ask all cardiologists to practice another Greek word,
nochi, which means “tolerance.” In other words, cardiologists
hould keep an open mind regarding the performance of PCI
ithout surgical backup until further data are available.
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esting Regeneration of Human Myocardium
ithout Knowing the Identity and the
umber of Effective Bone Marrow Cells
ransplanted: Are the Results Meaningful?
e read with great interest and attention the intriguing IACT
tudy by Strauer et al. in a recent issue of the Journal (1). We wish
o highlight a few points that might be crucial for the correct
nterpretation of the results.
The method used to derive the ejection fraction by ventriculog-
aphy is not specified in the study. If it was the biplane Simpson’s
ethod the conclusions might be questionable. This method, also
hen applied to echocardiographic images, requires significant
eometric assumptions and suffers from limited accuracy and
eproducibility (2). Both ventriculography and echocardiography
o not represent the optimal modalities (especially when compared
o cardiac magnetic resonance imaging) for repeated measurements
n small-sized follow-up studies (3). The sample size of the IACT
tudy seems inadequate to confer sufficient statistical power for
ntergroup comparisons.
Regional systolic functional analysis was used to detect changes
n infarct size. However, significant differences in the amount of
iable myocardium and the transmural extent of the necrosis in the
reated versus untreated dysfunctional myocardial segments may
ave potentially influenced the degree as well as the time-course of
unctional recovery in the two study groups (4).
Because the nature of the trial was nonrandomized, this study
as no control/placebo group. Therefore, the placebo effect and/or
dditional balloon expansion during cell administration cannot be
uled out.
The bone marrow cells (BMCs) used in the IACT study were
btained from a noncloned cell preparation, and, therefore, it is
mpossible to ascertain the number and nature of the putative
egenerating cells administered. Because of that, it cannot be
etermined whether the protocol used in this study does in fact test
he regenerative potential of the BMCs (5). Indeed, the amount of
yocardial regeneration in the treated patients, if any, cannot be
easured owing to technical and ethical reasons.
Even if we believe in the myocardial regenerative potential of
MCs, it has to be pointed out that the controversy surrounding
his topic has yet to be properly addressed (5). Strauer et al.
1) have further documented the safety and feasibility of BMC
njection in patients with chronic heart failure; however, their data
o not address some of the most controversial issues facing this
herapy.
In particular, because they could not reasonably deal with the
ssue of myocardial regeneration, Strauer et al. (1) offer an alter-
ative explanation for their results. This paracrine interpretation
rgues that the injected BMCs release angiogenic ligands, enhance
ardiomyocyte survival, and may recruit resident cardiac stem cells (CSCs) (5), but it is equally lacking in real data. Recently, it has
lso been proposed that apoptosis of transplanted cells modulates
ocal tissue reactions, leading to improved cardiac outcome (6).
hether these putative cell-related effects play any significant role
r whether they are specific to BMCs or just the consequence of
ny cell transplantation await the proper experiments.
What does remain clear is that at present there is no documented
echanistic explanation for the reported improvement in cardiac
unction in postinfarct patients treated with autologous BMCs.
Overall, we are persuaded that the relative contributions of the
ransplanted BMCs and/or the recruited CSCs on de novo
yogenesis and vasculogenesis will be unlikely resolved by small
linical trials. The identity of the therapeutic cells present in the
one marrow must be established and their biological properties
efined before planning large clinical trials.
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e appreciate the high interest in our recently published data,
ecause it raises some interesting concerns that were considered
efore initiating our investigation.
First, ever since myocardial stem cell therapy in humans was
rst reported in 2001 by our group (1), both the effectiveness and
he safety of this type of therapy in acute myocardial infarction
ave been increasingly established. This is now also relevant for old
i.e., chronic) myocardial infarction. The use of mononuclear bone
